By Colin KellaherShares of Iovance Biotherapeutics tumbled in premarket trading Wednesday after the biotechnology company said the U.S. Food and Drug Administration placed a clinical hold on a Phase 2 study of its LN-145 therapy in non-small cell lung cancer following the death of a study patient. Iovance shares, which closed Tuesday at $8.89, were recently down 26% to $6.59 in premarket trading. Iovance, which is studying LN-145 in certain patients with advanced non-small cell lung cancer who have poor prognosis following disease progression and limited treatment options, said the fatality is potentially related to the study's non-myeloablative lymphodepletion pre-conditioning regimen. The San Carlos, Calif., company said it will pause enrollment and the treatment regimen for new patients in the study during the clinical hold, adding that the hold has no impact on any of its other clinical trials. Write to Colin Kellaher at colin.kellaher@wsj.com(END) Dow Jones Newswires12-27-23 0739ET

Source: Wall Street Journal December 27, 2023 12:47 UTC